Acute Coronary Syndrome Pipeline

DelveInsight’s, “Acute Coronary Syndrome - Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Acute Coronary Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Acute Coronary Syndrome: Understanding

Acute Coronary Syndrome: Overview

Acute coronary syndrome (ACS) is a spectrum of clinical conditions resulting from sudden, reduced blood flow to the heart, typically caused by the rupture of an atherosclerotic plaque and subsequent thrombus formation in the coronary arteries. It encompasses three major entities: ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina, each varying in severity but sharing a common pathophysiological basis of myocardial ischemia. ACS is a critical manifestation of coronary heart disease (CHD), which remains a leading cause of mortality worldwide, accounting for nearly one-third of deaths in individuals over the age of 35. Unlike some forms of CHD that may remain silent or asymptomatic, ACS always presents with symptoms—commonly chest pain or discomfort, shortness of breath, nausea, and diaphoresis—and requires immediate medical attention to prevent irreversible cardiac damage or death. Prompt diagnosis and intervention are vital for improving survival and reducing complications.

Acute coronary syndrome (ACS) typically presents with sudden chest pain or discomfort, often described as pressure, tightness, or squeezing, which may radiate to the arms, neck, jaw, back, or upper abdomen. Common accompanying symptoms include shortness of breath, nausea or vomiting, profuse sweating (cold sweats), unexplained fatigue, and dizziness or lightheadedness. Some patients may also experience anxiety, palpitations, or even fainting. These symptoms indicate an urgent cardiac event requiring immediate medical evaluation and intervention.

The underlying pathophysiology of acute coronary syndrome (ACS) involves a sudden reduction in blood flow to a portion of the heart muscle, most commonly due to the rupture of an atherosclerotic plaque within a coronary artery, which triggers platelet aggregation and thrombus (clot) formation. This obstructs blood flow, leading to oxygen deprivation (ischemia) in the affected myocardial tissue. If left untreated, the ischemia can progress to irreversible myocardial cell death, or infarction. While plaque rupture and thrombosis are the predominant causes, ACS can also result from coronary artery vasospasm, either in the presence or absence of significant atherosclerosis, leading to transient but critical reductions in coronary perfusion. Additional contributing factors may include endothelial dysfunction, inflammation, and increased myocardial oxygen demand in the setting of reduced supply. The degree and duration of blood flow obstruction determine the clinical severity, ranging from unstable angina to non-ST elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI), with varying degrees of myocardial damage. 

The initial treatment of acute coronary syndrome (ACS) involves prompt administration of aspirin (300 mg) and anticoagulation with a heparin bolus followed by IV infusion, provided there are no contraindications. Dual antiplatelet therapy with clopidogrel or ticagrelor is also recommended, with the choice often guided by clinical context and cardiologist preference—ticagrelor is avoided in thrombolysis. Supportive care includes pain management with morphine or fentanyl, oxygen if hypoxic, and nitroglycerin for chest pain, though it must be used cautiously in inferior wall ischemia due to risk of hypotension. STEMI patients require urgent percutaneous coronary intervention (PCI) within 90 minutes or thrombolytics within 30 minutes if PCI is unavailable. NSTEMI and unstable angina are managed initially with medications and symptom control, followed by risk-based decisions on early or delayed catheterization. Continuous cardiac monitoring, early initiation of beta-blockers, statins, and ACE inhibitors, and cardiology admission are essential for all ACS cases. For patients unsuitable for PCI, coronary artery bypass grafting (CABG) or medical management may be considered based on individual risk factors and preferences.

"Acute Coronary Syndrome- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Coronary Syndrome pipeline landscape is provided which includes the disease overview and Acute Coronary Syndrome treatment guidelines. The assessment part of the report embraces, in depth Acute Coronary Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Coronary Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Acute Coronary Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Acute Coronary Syndrome.

 

Acute Coronary Syndrome Emerging Drugs Chapters

This segment of the Acute Coronary Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Acute Coronary Syndrome Emerging Drugs

• Vicagrel: Jiangsu vcare pharmaceutical technology co., LTD

Vicagrel is a collaborative project between Jiangsu Vcare and China Pharmaceutical University with with the company holding complete intellectual property rights to the program.  Vicagrel, based on its ingenious structural design, generates the active metabolite consistent with clopidogrel through a new initial metabolic pathway. Therefore, it is expected to successfully overcome the clinical challenge of clopidogrel resistance while avoiding the adverse drug interactions that occur when other drugs are co-administered with clopidogrel. Additionally, Vicagrel has a faster onset of action and a significantly lower dose, which means it has a more significant advantage in emergency medication and is expected to further reduce dose-related side effects. As a result, this product is expected to become a new type of antiplatelet drug with more stable efficacy and more controllable safety. Jiangsu Vcare PharmaTech Co., Ltd. successfully submitted a New Drug Application to the U.S. Food and Drug Administration for Vicagrel capsule, which is indicated to treat a range of thrombotic cardiovascular and cerebrovascular diseases, including acute coronary syndrome, ischaemic stroke, and peripheral arterial disease. Currently, the drug is in Preregistration stage of its development for the treatment of Acute Coronary Syndrome.

• Orticumab: Abcentra

Orticumab is an investigational, first-in-class fully human IgG1 monoclonal antibody developed by Abcentra, targeting oxidized low-density lipoprotein (oxLDL), a key driver of coronary artery inflammation and atherosclerotic plaque instability. Unlike traditional systemic anti-inflammatory therapies, orticumab offers a localized approach by binding specifically to malondialdehyde-modified apolipoprotein B-100, a unique epitope on oxLDL. This targeted action reduces macrophage activation in atherosclerotic plaques, potentially decreasing the risk of plaque rupture and subsequent acute coronary events. Currently, the drug is in Phase II stage of its development for the treatment of Acute Coronary Syndrome.

Further product details are provided in the report……..

Acute Coronary Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Acute Coronary Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

• Major  Players in Acute Coronary Syndrome

• There are approx.  5+ key companies which are developing the therapies for Acute Coronary Syndrome. The companies which have their Acute Coronary Syndrome drug candidates in the most advanced stage, i.e. Phase III include, DalCor Pharmaceuticals.

Stay ahead with in-depth analysis of the Acute Coronary Syndrome Market Foreacst-discover emerging therapies, epidemiology data and growth opportunities.

 

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• • Late stage products (Phase III)
• • Mid-stage products (Phase II)
• • Early-stage product (Phase I) along with the details of 
• • Pre-clinical and Discovery stage candidates
• • Discontinued & Inactive candidates

 

Route of Administration

Acute Coronary Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Acute Coronary Syndrome: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Coronary Syndrome therapeutic drugs key players involved in developing key drugs. 

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Coronary Syndrome drugs.

Acute Coronary Syndrome Report Insights

• Acute Coronary Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Acute Coronary Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Coronary Syndrome drugs?
• How many Acute Coronary Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Coronary Syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Coronary Syndrome therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Acute Coronary Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?